Cargando…

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab

We report a patient with idiopathic hypereosinophilic syndrome (I‐HES) who achieved remission with benralizumab after relapsing on mepolizumab. An 83‐year‐old man was admitted to Showa General Hospital after presenting with hypoxaemia and multiple erythematous lesions. He showed a marked increase in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Koki, Takahashi, Hidenori, Hayakawa, Nami, Iwasaki, Yoshinobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511777/ https://www.ncbi.nlm.nih.gov/pubmed/33005423 http://dx.doi.org/10.1002/rcr2.665

Ejemplares similares

Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2021)

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Requena, Gema, et al.
Publicado: (2021)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
por: Lachance, Madeleine, et al.
Publicado: (2022)

Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
por: Li, Lisha, et al.
Publicado: (2021)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
por: Cook, Alistair, et al.
Publicado: (2021)

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
por: Roufosse, Florence, et al.
Publicado: (2020)

PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME
por: Ogbogu, Princess, et al.
Publicado: (2023)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α – benralizumab
por: Kosałka-Węgiel, Joanna, et al.
Publicado: (2021)

Idiopathic hypereosinophilic syndrome with pulmonary hypertension
por: Zhang, Liping, et al.
Publicado: (2018)

Idiopathic hypereosinophilic syndrome presenting with liver mass: Report of two cases: Idiopathic hypereosinophilic syndrome and liver mass
por: shatery, Kamran, et al.
Publicado: (2011)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
por: Isoyama, Shoko, et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Idiopathic Hypereosinophilic Syndrome with Multiple Organ Involvement
por: Abo Shdid, Reham, et al.
Publicado: (2021)

Idiopathic Hypereosinophilic Syndrome Presenting With Embolic Stroke
por: Silva, Magda S, et al.
Publicado: (2021)

Idiopathic Hypereosinophilic Syndrome: A Case Report
por: Agudo, Margarida, et al.
Publicado: (2023)

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies
por: Lazzari, Chiara, et al.
Publicado: (2023)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
por: Caminati, Marco, et al.
Publicado: (2023)

Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay
por: Neto, Miguel Pedro de Queiroz, et al.
Publicado: (2017)

Idiopathic hypereosinophilic syndrome: A rare diagnosis in children
por: Pallesen, Kristine Appel Uldall, et al.
Publicado: (2020)

Idiopathic hypereosinophilic syndrome with cutaneous necrosis and multiorgan embolism
por: Wang, Huan, et al.
Publicado: (2019)

Idiopathic hypereosinophilic syndrome in hemodialysis patients: Case reports
por: Mutsuyoshi, Yuko, et al.
Publicado: (2021)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
por: Masumoto, Nami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_odd910diu9otnuv3kmiiollufp